Aptargroup

AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions and services for the prescription drug, consumer health care, injectables, active packaging, beauty, personal care, home care, and food and beverages. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sells dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aptargroup (ATR) reports robust Q4 results and strategic realignment

Aptargroup's Q4 performance reflects strong core sales growth and profitability, driven by the pharma and beauty segments, despite regional challenges.
Realignment initiatives aim to optimize operations and enhance market position, with a focus on cost management and sustainable growth opportunities.
While facing challenges such as volume declines and increased expenses, Aptar remains poised for growth with a positive outlook for the year ahead.
The company's strategic focus on capital efficiencies, innovation, and sustainability underscores its commitment to long-term success and profitability.

Aptar reports solid Q1 growth driven by Pharma and Beauty demand

Aptar's Q1 performance reflects growth in key segments, with a positive outlook for Q2. Strategic focus on operational efficiencies and new product innovations positions the company for continued success.

Aptargroup (ATR) reports solid Q2 performance and optimistic growth outlook

Aptargroup's Q2 2023 performance showcased strength in core sales growth, robust segmental performance, and a focus on sustainability and shareholder value.
While facing challenges in certain operational areas, the company remains optimistic about future growth prospects and is committed to addressing hurdles effectively.
With a positive outlook for Q3 and a strategic focus on innovation and sustainability, Aptar is well-positioned to capitalize on growth opportunities and drive long-term value creation.

Aptargroup reports 2% sales growth in Q3 driven by Pharma success

Aptargroup's Q3 performance reflects solid sales growth and profitability, driven by strength in Pharma and fragrance technologies.
The company's emphasis on innovation, sustainability, and governance underscores its commitment to long-term success and stakeholder value.
Despite challenges in the Beauty segment, Aptar's strategic focus on growth opportunities and cost optimization positions it well for future success.

Aptargroup (ATR) reports solid Q4 earnings, eyes Asia expansion

Aptargroup's Q4 2023 performance reflects steady growth, strong margins, and strategic initiatives for future expansion. While facing challenges in certain segments, the company's focus on innovation and sustainability, along with successful partnerships, positions it well for continued growth. Shareholders benefited from over $104 million returned in 2023.

Aptargroup (ATR) reports robust Q1 results, eyes pharma growth opportunities

Aptargroup's Q1 performance reflects a balanced growth trajectory with strengths in sustainability recognition and product innovation. While challenges in the Beauty segment persist, opportunities in pharma growth and margin improvement are key focus areas for future success.

Aptargroup (ATR) reports solid Q2 results, eyes growth opportunities

Aptargroup's Q2 performance reflects resilience and strategic focus on core business segments amidst market challenges.
The company's financial strength, sustainability recognition, and leadership continuity position it well for future growth.
Challenges in injectables and Beauty segments underscore the need for targeted strategies and market adaptation.
Opportunities lie in innovation, market expansion, and leveraging sustainability efforts for competitive advantage.

Aptar reports robust Q3 performance driven by pharma and food

Aptar's Q3 2024 performance reflects solid core sales growth and increased EPS, driven by strong demand in pharma and food segments. Challenges in the Beauty segment were offset by growth in personal care and home care markets.
Key strengths include operational improvements, acquisitions in the Pharma segment, and recognition for corporate excellence. Aptar's focus on innovation and efficiency presents opportunities for future growth.
While facing challenges in the Beauty segment and CFO transition, Aptar remains optimistic about growth prospects in Pharma and Closures segments, emphasizing innovation and market opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions, and services for the prescription drug, consumer health care, injectable, active packaging, beauty, personal care, home care, and food and beverages industries. It operates through the following segments: Pharma, Beauty and Home, and Food and Beverage. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

AptarGroup's (ATR) top and bottom lines improve on solid growth in the Pharma segment as well as in the food, personal care and home care markets during the July-September period.

AptarGroup (ATR) Q3 Earnings & Sales Top Estimates, Shares Up

Packaging Corp of America

PKG vs. ATR: Which Stock Is the Better Value Option?

PKG vs. ATR: Which Stock Should Value Investors Buy Now?

AptarGroup's (ATR) CEO Stephan Tanda on Q3 2020 Results - Earnings Call Transcript

AptarGroup (ATR) delivered earnings and revenue surprises of 19.05% and 7.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AptarGroup (ATR) Surpasses Q3 Earnings and Revenue Estimates

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR) today reported third quarter results for 2020 and provided an update related to COVID-19 including the Company's continued supply of essential products for critical industries. Third Quarter 2020 Summary Reported sales increased 8%, including positive effects of currency translation rates and recent acquisitions, and core sales increased 2% Strong reported and core growth in our Pharma segment Core sales growth in the food, person

Aptar Reports Third Quarter 2020 Results

AptarGroup's (ATR) third-quarter 2020 results are likely to reflect higher demand for pharmaceutical products amid the COVID-19 pandemic. However, weak beauty products sales will negate these gains.

AptarGroup (ATR) Suffers From Weak End Markets Amid Pandemic

AptarGroup (ATR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline

The company has handled COVID-19 fairly well and has made it through the worst of it with minimal damage.

AptarGroup: Breakout Confirmed

AptarGroup (ATR) reported earnings 30 days ago. What's next for the stock?

Why Is AptarGroup (ATR) Up 0.2% Since Last Earnings Report?

AptarGroup (ATR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why AptarGroup (ATR) Stock Might be a Great Pick

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc.

Aptar’s Emission Reduction Goals Validated by Science Based Target Initiative (SBTi)

Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.

Reasons to Hold AptarGroup (ATR) Stock in Your Portfolio Now

AptarGroup (ATR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About AptarGroup (ATR) Rating Upgrade to Strong Buy

AptarGroup's (ATR) core sales growth in the Pharma segment in Q2 is partly offset by decline in core sales in other segments due to the coronavirus pandemic.

AptarGroup's (ATR) Earnings & Sales Beat Estimates in Q2

AptarGroup Inc. (ATR) CEO Stephan Tanda on Q2 2020 Results - Earnings Call Transcript

AptarGroup (ATR) delivered earnings and revenue surprises of 17.65% and 6.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AptarGroup (ATR) Q2 Earnings and Revenues Beat Estimates

Aptar Reports Second Quarter 2020 Results

AptarGroup (ATR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AptarGroup (ATR) Might Surprise This Earnings Season?

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, announced today that Kimberly Y. Chainey will join the company as its Executive Vice President, Global General Counsel, effective July 27, 2020. Chainey will be responsible for the company's global legal affairs and will become a member of Aptar’s Executive Committee. “We are delighted to welcome Kim Chainey to Aptar. Her breadth of exp

Aptar Appoints Kimberly Y. Chainey as EVP General Counsel

AptarGroup's (ATR) Q2 performance might have been adversely impacted by lackluster demand due to the coronavirus crisis-related near-term uncertainties.

Dismal End-Market Demand & Cost Woes Impact AptarGroup

Berry Global Group

Cie Generale des Etablissements Michelin SCA

Myers

Trinseo PLC

Rubber and plastics stocks have lagged the market rebound. Commodity prices are a concern, but these five stocks have hopes of catching up.

5 Rubber and Plastics Stocks Ready to Bounce

Why Is AptarGroup (ATR) Up 4% Since Last Earnings Report?

AptarGroup (ATR) registers solid core sales growth in the Pharma segment in Q1, partly offset by decline in core sales in other segments on the coronavirus crisis.

AptarGroup's (ATR) Earnings & Sales Top Estimates in Q1

AptarGroup Inc. (ATR) CEO Stephan Tanda on Q1 2020 Results - Earnings Call Transcript

AptarGroup (ATR) delivered earnings and revenue surprises of 5.68% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Aptargroup Stock (ATR)